Agilent Announces Eczema Research Collaboration
Agilent Technology has announced a collaboration with researchers at the University of Sheffield and the University of Manchester to investigate the risk factors surrounding atopic eczema, a chronic skin condition that affects one in five children and one in 12 adults.
Agilent Technology (Santa Clara, California, USA) has announced a collaboration with researchers at the University of Sheffield and the University of Manchester to investigate the risk factors surrounding atopic eczema (atopic dermatitis), a chronic skin condition that affects one in five children and one in 12 adults.
The study will follow a group of 175 babies during their first year of life to see how their skin matures, and identify which babies are most at risk of developing eczema. This early identification is crucial to preventing eczema from developing further, and could also potentially prevent the development of other inflammatory skin disorders.
“A growing body of evidence suggests a critical role for the skin barrier in the development and course of atopic eczema. A greater understanding of skin barrier optimization from birth, promises to identify susceptible individuals early on, and enable novel therapeutic options to improve standards of neonatal skin care and prevent clinical eczema development,” said Simon G. Danby, the lead researcher of the Skin Testing for Atopic eczema Risk (STAR) study and research fellow in the Sheffield Dermatology Research group at the University of Sheffield.
For more information, please visit: www.agilent.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
